Click here to view the United Healthcare (UHC) Medical Policy Updates » December 2024 United…
BCBS Kansas City Medical Policy Updates – August 2022
Click here to view the Blue Cross Blue Shield BCBS Kansas City Medical Policy Updates »
August 2022 BCBS Kansas City Medical Policy Updates:
- Actemra (tocilizumab)
- Adcetris (brentuximab vedotin)
- Aducanumab for Alzheimer Disease
- Aducanumab for Alzheimer Disease
- Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension
- Aldurazyme (laronidase)
- Aliqopa (copanlisib)
- Alpha Proteinase Inhibitors
- Arcalyst (rilonacept)
- Ayvakit (avapritinib)
- Azacitidine
- Bavencio (avelumab)
- Benlysta (belimumab)
- Besponsa (inotuzumab ozogamicin)
- Bevacizumab (oncology)
- Bevacizumab (ophthalmic)
- Blenrep (belantamab mafodotin-blmf)
- Blincyto (blinatumomab)
- Botulinum Toxin
- C1 Esterase Inhibitors
- Cablivi (caplacizumab-yhdp)
- Carbaglu (carglumic acid)
- Cerezyme (imiglucerase)
- Cimzia (certolizumab pegol)
- Cimzia (certolizumab)
- Cinqair (reslizumab)
- Cladribine IV
- Clotting Factor and Coagulant Blood Products
- Cosela (Trilaciclib)
- Crysvita (burosumab-twza)
- Cystaran (cysteamine)
- Daraprim (pyrimethamine)
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Step Therapy
- Duopa (carbidopa-levodopa enteral suspension)
- Elaprase (idursulfase)
- Elelyso (taliglucerase alfa)
- Elitek (rasburicase)
- Enbrel (etanercept)
- Enjaymo (sutimlimab-jome)
- Enspryng (satralizumab)
- Entyvio (vedolizumab)
- Evkeeza (evinacumab-dgnb)
- Eysuvis (loteprednol etabonate)
- Fabrazyme (agalsidase beta)
- Fasenra (benralizumab)
- Fensolvi (leuprolide acetate)
- GLP-1 Agonists
- Gout Medications ST policy
- Hemlibra (emicizumab-kxwh)
- Herceptin (trastuzumab) and biosimilars
- Hip Arthroplasty_26th Ed_GMM_FINAL DRAFT_version 2
- Humira (adalimumab)
- Ibandronate injection
- Ibrance (palbociclib)
- Ilaris (canakinumab)
- Ilumya (tildrakizumab-asmn)
- Imcivree (setmelanotide)
- Immune Globulin Therapy
- Intra-articular Hyaluronan Injections for Osteoarthritis
- Istodax (romidepsin)
- Jynarque (tolvaptan)
- Kadcyla (ado-trastuzumab emtansine)
- Kalbitor (ecallantide)
- Keytruda (pembrolizumab)
- Kisqali_Kisqali Femara (ribociclib)
- Knee Arthroplasty Total_26th ed_GMM_FINAL DRAFT_version 2
- Lemtrada (alemtuzumab)
- Libtayo (cemiplimab-rwlc)
- Long-Acting Opioid Step Therapy Policy
- Lumizyme (alglucosidase alfa)
- Lupkynis (voclosporin)
- Margenza (margetuximab-cmkb)
- Medical Cannabis for the Treatment of Pain and Spasticity
- Mepsevii (vestronidase-aslfa-vjbk)
- Monjuvi (tafasitamab-cxix)
- Mozobil (plerixafor)
- Myalept (metreleptin)
- Mylotarg (gemtuzumab ozogamicin)
- Naglazyme (galsulfase)
- Natpara (parathyroid hormone)
- Nexviazyme (avalglucosidase alfa-ngpt)
- Northera (droxidopa)
- Nucala (mepolizumab)
- Nurtec (rimegepant)
- Ocrevus (ocrelizumab)
- Onpattro (patisiran)
- Ophthalmic VEGF Inhibitors
- Orencia (abatacept)
- Orgovyx (relugolix)
- Orladeyo (berotralstat)
- Parenteral Iron
- Parsabiv (etelcalcetide)
- Pepaxto (melphalan flufenamide)
- Perjeta (pertuzumab)
- Poteligeo (mogamulizmuab-kpkc)
- Progesterone Therapy as a Technique to Reduce Preterm Birth in High-Risk Pregnancies
- Provigil Nuvigil Step Therapy
- Pyrukynd (mitapivat)
- Reblozyl (luspatercept-aamt)
- Repository Corticotropin Injection
- Reyvow (lasmiditan)
- Rituximab and Biosimilars
- Rylaze (asparaginase)
- Saphnelo (anifrolumab-fnia)
- Short-Acting Fentanyl
- Skyrizi (risankizumab-rzaa)
- Soliris (eculizumab)
- Spravato (esketamine)
- Stelara (ustekinumab)
- Strensiq (asfotase alfa)
- Takhzyro (lanadelumab-flyo)
- Tavalisse (fostamatinib)
- Tazverik (tazemetostat)
- Tepezza (teprotumumab-trbw)
- Testosterone Replacement Therapies
- Thrombate III [Antithrombin III (Human)]
- Treatment for Duchenne Muscular Dystrophy
- Tysabri (natalizumab)
- Ubrelvy (ubrogepant)
- Ultomiris (ravulizumab-cwvz)
- Verquvo (vericiguat)
- Vimizim (elosulfase alfa)
- VPRIV (velaglucerase alfa)
- Vyepti (eptinezumab)
- Vyxeos (daunorubicin-cytarabine)
- Xermelo (telotristat)
- Xolair (omalizumab)
- Yervoy (ipilimumab)
- Zaltrap (ziv-aflibercept)
- Zejula (niraparib)
- Zinplava (bezlotoxumab)
- Zokinvy (lonafarnib)
- Zulresso (brexanolone)
Click here to view the Blue Cross Blue Shield BCBS Kansas City Medical Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!
Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
